Table 2.
No. | Age (y) | Sex | HP | API2‐MALT1 | Treatment | Eradication regimen | Outcome | Gastric mucosa atrophy | Bacterial species (PCR) | NHPH diagnosis (histological) | NHPH after eradication | Authors |
---|---|---|---|---|---|---|---|---|---|---|---|---|
A1 | 36 | M | N | N | Eradication | LAC | CR | (‐) | H suis | N | N | Current study |
A2 | 37 | M | N | N | Eradication | LAC | CR | (‐) | H suis | P | N | |
A3 | 42 | M | P | N | Eradication | LAC | CR | C‐2 | H suis | N | N | |
A4 | 45 | M | N | N | Eradication | LAC | CR | (‐) | H suis | N | N | |
B1 | ND | ND | N | ND | Eradication | LAC | CR | ND | ND | P | N | Okiyama et al10 |
B2 | ND | ND | N | ND | Eradication | LAC | CR | ND | ND | P | N | Okiyama et al10 |
Abbreviations: CR, complete response; F, female; HP, H pylori infection; LAC, lansoprazole, amoxicillin, clarithromycin; M, male; MALT, mucosa‐associated lymphoid tissue; N, negative; ND, not described; NHPH, non‐H pylori Helicobacter; P, positive.